Jasper Therapeutics, Inc.
JSPRW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001788028
No open-market purchases or sales by Jasper Therapeutics, Inc. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $187.1K in total; no superinvestor holds it.
Other share classesJSPR
13F holders, Q4 2022
Institutional positions in Jasper Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- 0 vs. Q3 2022
- Shares held
- 1.31M
- −175.0K (−11.8%) vs. Q3 2022
- Total value
- $55.5K
- −$79.5K (−58.9%) vs. Q3 2022
- New holders
- 1
- 1 more added
- Sold out
- 1
- 3 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JSPRW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $187.1K |
| Q1 2026 | 8 | $371.6K |
| Q4 2025 | 10 | $761.1K |
| Q3 2025 | 9 | $1.09M |
| Q2 2025 | 7 | $383.1K |
| Q1 2025 | 6 | $129.0K |
| Q4 2024 | 5 | $193.1K |
| Q3 2024 | 5 | $625.7K |
| Q2 2024 | 5 | $618.9K |
| Q1 2024 | 4 | $538.5K |
| Q4 2023 | 6 | $236.3K |
| Q3 2023 | 8 | $120.7K |
| Q2 2023 | 11 | $344.6K |
| Q1 2023 | 11 | $430.9K |
| Q4 2022 | 15 | $55.5K |
| Q3 2022 | 15 | $135.0K |
| Q2 2022 | 15 | $179.0K |
| Q1 2022 | 16 | $554.0K |
| Q4 2021 | 16 | $2.97M |
| Q3 2021 | 16 | $3.67M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding Jasper Therapeutics, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Highbridge Capital Management LLC | – | $16.0K | 0.00% | – | – |
| Ionic Capital Management LLC | 459,391 | $13.8K | 0.00% | 00.0% | Unchanged |
| Owl Creek Asset Management, L.P. | 267,189 | $8.02K | 0.00% | −107,644−28.7% | Reduced |
| Tenor Capital Management Co., L.P. | 250,000 | $7.50K | 0.00% | 00.0% | Unchanged |
| Privium Fund Management B.V. | 98,202 | $3.33K | 0.00% | +100+0.1% | Added |
| Zazove Associates LLC | 65,456 | $2.00K | 0.00% | 00.0% | Unchanged |
| Equitec Proprietary Markets, LLC | 45,856 | $1.38K | 0.00% | 00.0% | Unchanged |
| Shaolin Capital Management LLC | 20,420 | $1.00K | 0.00% | −41,222−66.9% | Reduced |
| Cowen and Company, LLC | 32,590 | $977 | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 25,059 | $752 | 0.00% | 00.0% | Unchanged |
| Walleye Trading LLC | 14,095 | $423 | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 10,646 | $319 | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 22,524 | $0 | 0.00% | −6,940−23.6% | Reduced |
| SkyView Investment Advisors, LLC | 302 | $0 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 50 | $0 | 0.00% | +50 | New |
| UBS Group AG | 0 | $0 | 0.00% | −19,296−100.0% | Sold out |